Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Carboxylic Acids and Dapagliflozin in T2D with Fatty Liver
NCT02279407Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Omega-3 carboxylic acids, dapagliflozin in non-alcoholic fatty liver disease (NAFLD), sponsored by AstraZeneca. Started Jan 2015; status: completed.
02
Drugs
Omega-3 carboxylic acidsdapagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02279407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02279407.